연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
2151. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.
Shin J1, Koh Y1, Yoon SH2, Cho JY2, Kim DY3, Lee KH3, Kim HJ4, Ahn JS4, Kim YK4, Park J5, Sohn SK6, Moon JH6, Lee YJ6, Yoon S7, Lee JO8, Cheong JW9, Kim KH10, Kim SH11, Kim HG12, Kim H13, Nam SH14, Do YR15, Park SG16, Park SK17, Bae SH18, Song HH19, Shin DY20, Oh D21, Kim MK22, Jung CW23, Park S1, Kim I1.
Cancer Med. 2018 May;7(5):1814-1823. doi: 10.1002/cam4.1450. Epub 2018 Mar 25.
Link
2150. Temporal trajectory of quality of life and its predictors in recipients of hematopoietic stem cell transplantation.
Kim R1, Son KL2, Lee KM3,4, Choi Y1, Hong J1, Shin DY1, Koh Y1, Hahm BJ5, Kim I6,7.
Ann Hematol. 2018 Aug;97(8):1407-1415. doi: 10.1007/s00277-018-3319-4. Epub 2018 Apr 3.
Link
2149. Efficacy of adjuvant radiotherapy in the intracranial hemangiopericytoma.
Jeon SH, Park S-H, Kim JW, Park C-K, Paek SH, Kim IH
J Neuro-Oncol 2018 May ;137(3):567-573
Link
2148. Survival gain with re-Op/RT for recurred high-grade gliomas depends upon risk groups
Chun SJ, Park SH, Park CK, Kim JW, Kim TM, Choi SH, Lee ST, Kim IH..
Radiother Oncol. August 2018;128(2):254-259.
Link
2147. Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study.
Wee CW, Kim IH, Park CK, Kim JW, Dho YS, Ohka F, Aoki K, Motomura K, Natsume A, Kim N, Suh CO, Chang JH, Kim SH, Cho WK, Lim DH, Nam DH, Choi JW, Kim IA, Kim CY, Oh YT, Cho O, Chung WK, Kim SH, Kim E.
Radiother Oncol. 2018 Nov;129(2):3437-351.
Link
2146. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.
Kim S1, Kim TM1,2, Kim DW1,2, Kim S1, Kim M1, Ahn YO1, Keam B1,2, Heo DS1,2.
Cancer Res Treat. 2018 Oct 10. doi: 10.4143/crt.2018.052. [Epub ahead of print]
Link
2145. Aberrant GATA2 epigenetic dysregulation induces a GATA2/GATA6 switch in human gastric cancer.
Song SH, Jeon MS, Nam JW, Kang JK, Lee YJ, Kang JY, Kim HP, Han SW, Kang GH, Kim TY.
ONCOGENE 2018 Feb 22;37(8):993-1004.
Link
2144. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.
Cha Y, Kim HP, Lim Y, Han SW, Song SH, Kim TY
MOL ONCOL 2018 Jun;12(7):993-1003.
Link
2143. A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.
Lee DW, Lee KH, Kim HJ, Kim TY, Kim JS, Han SW, Oh DY, Kim JH, Im SA, Kim TY.
BMC CANCER 2018 Mar 5;18(1):252.
Link
2142. Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells.
Cheon SK, Kim HP, Park YL, Jang JE, Lim Y, Song SH, Han SW, Kim TY.
MOL ONCOL 2018 Aug;12(8):1398-1409.
Link